RIBON THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ribontx.com
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05215808
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, Australia
🇦🇺Veracity Clinical Research, Woolloongabba, Queensland, Australia
🇳🇿Optimal Clinical Trials, Auckland, New Zealand
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
Phase 1
Active, not recruiting
- Conditions
- Advanced Squamous Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05127590
- Locations
- 🇺🇸
Helen F. Graham Cancer Center (Christiana Care), Newark, Delaware, United States
🇺🇸Hematology and Oncology Clinic, Baton Rouge, Louisiana, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04053673
- Locations
- 🇺🇸
SCRI-Sarasota/Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath